IL17A and chronic kidney disease: The pivotal contribution of IL-17α in the progression of CKD is strengthened by the restoration of glomerular barrier impermeability and the attenuation of pro-fibrotic and pro-inflammatory genes after monoclonal antibody blockade of the cytokine in rodent models [43,44].